NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 15th May 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Anna Pracz Present for all items
4. Dr Alistair Patton Present for all items
5. Dr Andrew Makin Present for all items
6. Dr Bushra Hasnie Present for all items
7. Dr Daniel Gallacher Present for all items
8. Dr Natalia Kunst Present for all items
9. Dr Rhiannon Owen Present for all items
10. Dr Stuart Williams Present for all items
11. Dr Toby Smith Present for all items
12. Dr Warren Linley Present for all items
13. Gabriel Rogers  Present for all items
14. Lisa Attrill Present for all items
15. Nigel Westwood Present for all items
16. Professor David McAllister Present for all items
17. Tony Wootton Present for all items
18. Vanessa Danielson Present for all items

NICE staff (key players) present

Emily Crowe, Associate Director Present for all items

Jeremy Powell, Project Manager Present for all items

Staff member, Heath Technology Assessment Adviser Present for all items

Staff member, Heath Technology Assessment Analyst Present for all items

Lousie Jones, Administrator, Technology Appraisals Present for all items

External assessment group representatives present

Dolapo Ayansina, Aberdeen HTA Group Items 1.1 to 4.1.3

Mary Kilonzo, Aberdeen HTA Group Items 1.1 to 4.1.3

Graham Scotland, Aberdeen HTA Group Items 1.1 to 4.1.3

Sachin Kumar, Aberdeen HTA Group Items 1.1 to 4.1.3

Clinical, Patient & NHS England experts present

Peter Clark, NHS CDF clinical lead Present for all items

Anna Bennett, patient expert nominated by the BRAFG Patient Support Group

Items 1.1 to 4.1.3

Steve Bennett, patient expert, nominated by Guts UK Items 1.1 to 4.1.3

Mark Saunders, Consultant Clinical Oncologist, clinical expert nominated by Servier laboratories Items 1.1 to 4.1.3

Harpreet Wasan, Consultant & Professor in Oncology, clinical expert nominated by NICE

Items 1.1 to 4.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Baljit Singh, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Francis Drobniewski, Mark Tanner, Peter Wheatley-Price, Veline L’Esperance and Hatim Abdulhussein.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 11th April 2024.

1. **Appraisal of** [**trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta11390) 
   1. Part 1 – Open session
      1. The chair, Baljit Singh, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Servier.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11390).
      3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Andrew Makin (clinical), Rhiannon Owen (cost) and Tony Wootton (lay).
   2. Part 2 –Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus..
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11390>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 13th June and will start promptly at 9am.